MELISSA HAKES: Open Payments
NPI 1659149847 · FLAGSTAFF, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$924 in 26 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $1,029 · 2025 $924
Food & beverage: $924
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 2 | $229 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $128 |
| ABBVIE INC. | 1 | $125 |
| Janssen Biotech, Inc. | 3 | $85 |
| Gilead Sciences, Inc. | 4 | $71 |
| GENZYME CORPORATION | 2 | $64 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $57 |
| Lilly USA, LLC | 2 | $56 |
| Phathom Pharmaceuticals, Inc. | 1 | $36 |
| Ardelyx, Inc. | 1 | $32 |
Products named: REZDIFFRA, MAVYRET, ENTYVIO, DUPIXENT, TREMFYA, XIFAXAN, OMVOH, VOQUEZNA.
Industry payments across AZ — which companies pay providers there.
